The 28th CSCO Annual Meeting Opens in Jinan

The 28th CSCO Annual Meeting Opens in Jinan

2025.09.14
This September, the city of Jinan welcomed one of China’s most prestigious academic events in oncology. The 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2025) officially opened on the morning of September 11th, gathering experts, clinicians, researchers, and industry representatives from across the country. Multiple academicians and internationally renowned oncologists attended the ceremony to discuss new progress in cancer prevention and treatment under the theme “Standardized Treatment, Innovation-Driven Leadership”—together charting a new global blueprint for the fight against cancer.
Professors Ning Xie & Lingzhi Xu: ADC vs. Targeted Therapy + Endocrine Therapy in the Post-CDK4/6i Era

Professors Ning Xie & Lingzhi Xu: ADC vs. Targeted Therapy + Endocrine Therapy in the Post-CDK4/6i Era

2025.09.13
For patients with hormone receptor–positive (HR+) advanced breast cancer who progress after treatment with CDK4/6 inhibitors, should clinicians choose antibody–drug conjugates (ADCs) or a combination of targeted therapy plus endocrine therapy (ET)? At the 2025 Summer Breast Cancer Forum · Northern Salon, the “Debate” session addressed this very question. Professor Ning Xie of Hunan Cancer Hospital and Professor Lingzhi Xu of the Second Affiliated Hospital of Dalian Medical University presented evidence-based arguments for ADCs and for targeted therapy + ET, respectively. In this Oncology Frontier feature, they further elaborate on their viewpoints.
Professor Yunjiang Liu: OPS and MDT as Twin Engines Driving Breast Cancer Treatment into the Era of “Precision Breast-Conservation”

Professor Yunjiang Liu: OPS and MDT as Twin Engines Driving Breast Cancer Treatment into the Era of “Precision Breast-Conservation”

2025.09.12
From August 27–31, 2025, the 16th Yan Zhao Breast Cancer Forum was held grandly in Shijiazhuang. The event was jointly organized by the Breast Cancer Committee of the Hebei Anti-Cancer Association and several other specialty committees, co-organized by the Beijing Breast Disease Prevention and Treatment Society, and hosted by the Fourth Hospital of Hebei Medical University and the Hebei Breast Disease Diagnosis and Treatment Center. This year’s forum focused on multidisciplinary innovations and cutting-edge concepts in breast cancer management, aiming to advance standardized care and elevate regional treatment standards. At the meeting, Oncology Frontier invited the conference chair, Professor Yunjiang Liu of the Fourth Hospital of Hebei Medical University, for an in-depth interview. He discussed the core principles of oncoplastic surgery (OPS) in breast-conserving surgery, shared clinical experience and outcomes from the multidisciplinary team (MDT) model, and offered forward-looking perspectives on promoting greater uniformity in breast cancer care across the region and nationwide.
International Dialogue | ASH President-Elect Prof. Robert Negrin Visits Yanda Ludaopei Hospital for a Deep-Dive Conversation with Prof. Lu Peihua on the Future of Cell Therapy

International Dialogue | ASH President-Elect Prof. Robert Negrin Visits Yanda Ludaopei Hospital for a Deep-Dive Conversation with Prof. Lu Peihua on the Future of Cell Therapy

2025.09.04
The completion and smooth relocation of the new Hebei Yanda Ludaopei Hospital campus mark a major step forward for the Ludaopei Medical Group’s clinical capacity. On this occasion, internationally renowned hematologist Professor Robert Negrin—Director of the Blood and Marrow Transplantation Program at Stanford University and President-Elect of the American Society of Hematology (ASH)—visited the hospital for an in-depth exchange with Professor Lu Peihua, who leads the Ludaopei Medical Group. Their discussion centered on the evolution of cellular therapies, clinical challenges in CAR-T, and opportunities for global collaboration. Both sides emphasized that cross-border cooperation and open academic exchange are essential engines driving progress in hematologic disease care. Oncology Frontier – Hematology Frontier presents key takeaways from this Sino-U.S. dialogue to offer both practical reference and insight for the cell therapy community.